ArticleInternational journal of pharmaceutics: X2019
Development and characterization of liposomal formulation of bortezomib.
Article in International journal of pharmaceutics: X, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Nanomedicine-Based Strategies for Multiple Myeloma Therapy.International journal of nanomedicine · 2026Review
- Dissolution Enhancement of Lycopene Compacts by Liquisolid Technique.Turkish journal of pharmaceutical sciences · 2025Article
- Bone Marrow-Targeted Liposomes Loaded with Bortezomib Overcome Multiple Myeloma Resistance.ACS nano · 2025Article
- Nanoparticle-in-Hydrogel Delivery System for the Sequential Release of Two Drugs.Pharmaceutics · 2025Article
- Recent advances in targeted drug delivery systems for multiple myeloma.Journal of controlled release : official journal of the Controlled Release Society · 2024Review
- Prospect of Gold Nanoparticles in Pancreatic Cancer.Pharmaceutics · 2024Review
- Harnessing Nanotechnology: Emerging Strategies for Multiple Myeloma Therapy.Biomolecules · 2024Review
- A novel liposomal formulation for ocular delivery of caspofungin: an experimental study by quality by design-based approach.Therapeutic delivery · 2024Article
- Optimized Liposomal Delivery of Bortezomib for Advancing Treatment of Multiple Myeloma.Pharmaceutics · 2023Article
- Development and Optimisation of Inhalable EGCG Nano-Liposomes as a Potential Treatment for Pulmonary Arterial Hypertension by Implementation of the Design of Experiments Approach.Pharmaceutics · 2023Article
- Liposomal Nanomedicine: Applications for Drug Delivery in Cancer Therapy.Nanoscale research letters · 2021Review
- Targeting the ubiquitin-proteasome system in a pancreatic cancer subtype with hyperactive MYC.Molecular oncology · 2020Article
- Complete Tumor Regression by Liposomal Bortezomib in a Humanized Mouse Model of Multiple Myeloma.HemaSphere · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bortezomib is a proteasome inhibitor used for the treatment of multiple myeloma. The poor pharmacokinetic profile and off-target adverse effects provide a strong incentive to develop drug delivery systems for bortezomib. In the past, liposomal encapsulation has been proven to improve the therapeutic index of a variety of anti-neoplastic therapeutics. Here, we developed and characterized liposomal bortezomib formulations in order to find the most optimal loading conditions. Polyols were used to entrap bortezomib inside the liposomes as boronate ester via a remote loading strategy. Effect of various polyols, incubation duration, temperature, and total lipid concentration on loading efficiency was examined. Moreover, the effect of drug/lipid ratio on the release kinetics was studied. Loading efficiency was maximal when using meglumine plus mannitol as entrapping agents. Loading at room temperature was better than at 60 °C and loading efficiency was increased with increasing total lipid concentrations. There was a positive correlation between drug/lipid ratio and released amount of bortezomib.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.